Boehme AK, Esenwa C, Elkind MSV (2017) Stroke risk factors, genetics, and prevention. Circ Res 120:472–495. https://doi.org/10.1161/CIRCRESAHA.116.308398

Article  CAS  PubMed  PubMed Central  Google Scholar 

Meschia JF, Brott T (2018) Ischaemic stroke. Euro J Neurol 25:35–40. https://doi.org/10.1111/ene.13409

Article  CAS  Google Scholar 

Saver JL (2016) Cryptogenic stroke. N Engl J Med 375:e26. https://doi.org/10.1056/NEJMc1609156

Article  PubMed  Google Scholar 

Schäbitz WR, Köhrmann M, Schellinger PD et al (2020) Embolic stroke of undetermined source: gateway to a new stroke entity? Am J Med 133:795–801. https://doi.org/10.1016/j.amjmed.2020.03.005

Article  CAS  PubMed  Google Scholar 

Hart RG, Diener HC, Coutts SB et al (2014) Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol 13:429–438. https://doi.org/10.1016/S1474-4422(13)70310-7

Article  PubMed  Google Scholar 

Hart RG, Catanese L, Perera KS et al (2017) Embolic stroke of undetermined source: a systematic review and clinical update. Stroke 48:867–872. https://doi.org/10.1161/STROKEAHA.116.016414

Article  PubMed  Google Scholar 

Gladstone DJ, Spring M, Dorian P et al (2014) Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med 370:2467–2477. https://doi.org/10.1056/NEJMoa1311376

Article  CAS  PubMed  Google Scholar 

Aguilar M, Hart R, Pearce L (2006) Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. In: The Cochrane Collaboration (ed) Cochrane database of systematic reviews. Wiley, Chichester

Google Scholar 

Hart RG, Pearce LA, Aguilar MI (2007) Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146:857. https://doi.org/10.7326/0003-4819-146-12-200706190-00007

Article  PubMed  Google Scholar 

Ruff CT, Giugliano RP, Braunwald E et al (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383:955–962. https://doi.org/10.1016/S0140-6736(13)62343-0

Article  CAS  PubMed  Google Scholar 

Tawfik A, Bielecki J, Krahn M et al (2016) Systematic review and network meta-analysis of stroke-prevention treatments in patients with atrial fibrillation. CPAA 8:93–107. https://doi.org/10.2147/CPAA.S105165

Article  CAS  Google Scholar 

Chao TF, Liu CJ, Chen SJ et al (2012) Atrial fibrillation and the risk of ischemic stroke: does it still matter in patients with a CHA2 DS2-VASc score of 0 or 1? Stroke 43:2551–2555. https://doi.org/10.1161/STROKEAHA.112.667865

Article  CAS  PubMed  Google Scholar 

Hariharan NN, Patel K, Sikder O et al (2022) Oral anticoagulation versus antiplatelet therapy for secondary stroke prevention in patients with embolic stroke of undetermined source: a systematic review and meta-analysis. Eur Stroke J 7:92–98. https://doi.org/10.1177/23969873221076971

Article  PubMed  PubMed Central  Google Scholar 

Geisler T, Keller T, Martus P et al (2023) Apixaban versus aspirin for embolic stroke of undetermined source. NEJM Evid. https://doi.org/10.1056/EVIDoa2300235

Article  PubMed  Google Scholar 

Kamel H, Longstreth WT, Tirschwell DL et al (2024) Apixaban to prevent recurrence after cryptogenic stroke in patients with atrial cardiopathy: the ARCADIA randomized clinical trial. JAMA 331:573. https://doi.org/10.1001/jama.2023.27188

Article  CAS  PubMed  Google Scholar 

Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535–b2535. https://doi.org/10.1136/bmj.b2535

Article  PubMed  PubMed Central  Google Scholar 

Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds) (2022) Cochrane handbook for systematic reviews of interventions version 63 (updated February 2022). Cochrane Training, Cochrane

Google Scholar 

Sterne JAC, Savović J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. https://doi.org/10.1136/bmj.l4898

Article  PubMed  PubMed Central  Google Scholar 

Diener HC, Sacco RL, Easton JD et al (2019) Dabigatran for prevention of stroke after embolic stroke of undetermined source. N Engl J Med 380:1906–1917. https://doi.org/10.1056/NEJMoa1813959

Article  CAS  PubMed  Google Scholar 

Hart RG, Sharma M, Mundl H et al (2018) Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med 378:2191–2201. https://doi.org/10.1056/NEJMoa1802686

Article  CAS  PubMed  Google Scholar 

Healey JS, Connolly SJ, Gold MR et al (2012) Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 366:120–129. https://doi.org/10.1056/NEJMoa1105575

Article  CAS  PubMed  Google Scholar 

Kamel H, Okin PM, Elkind MSV, Iadecola C (2016) Atrial fibrillation and mechanisms of stroke: time for a new model. Stroke 47:895–900. https://doi.org/10.1161/STROKEAHA.115.012004

Article  PubMed  PubMed Central  Google Scholar 

Singer DE, Ziegler PD, Koehler JL et al (2021) Temporal association between episodes of atrial fibrillation and risk of ischemic stroke. JAMA Cardiol 6:1364. https://doi.org/10.1001/jamacardio.2021.3702

Article  PubMed  PubMed Central  Google Scholar 

Veltkamp R, Pearce LA, Korompoki E et al (2020) Characteristics of recurrent ischemic stroke after embolic stroke of undetermined source: secondary analysis of a randomized clinical trial. JAMA Neurol 77:1233. https://doi.org/10.1001/jamaneurol.2020.1995

Article  PubMed  Google Scholar 

Hirsh BJ, Copeland-Halperin RS, Halperin JL (2015) Fibrotic atrial cardiomyopathy, atrial fibrillation, and thromboembolism. J Am Coll Cardiol 65:2239–2251. https://doi.org/10.1016/j.jacc.2015.03.557

Article  PubMed  Google Scholar 

Connolly SJ, Eikelboom J, Joyner C et al (2011) Apixaban in patients with atrial fibrillation. N Engl J Med 364:806–817. https://doi.org/10.1056/NEJMoa1007432

Article  CAS  PubMed  Google Scholar